Developer docs
API playgroundTry for free, no card

Search company profiles

ChemoMetec

Full company profile

uuid000796a

Namestring
ChemoMetec
Legal namestring
ChemoMetec A/S
Websiteurl
chemometec.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

ChemoMetec A/S, founded in 1997 and headquartered in Allerød, Denmark, designs, manufactures, and sells automated cell counting and analysis instruments used by pharmaceutical, biotechnology, and academic customers to quantify cells in drug development, bioprocessing, and quality control. Its core technology is fluorescence-based image cytometry that uses proprietary, volume-calibrated disposable cassettes (Via1, Via2, Via3) to eliminate the subjectivity and pipetting error inherent in manual trypan-blue counting. The product portfolio spans the NucleoCounter family (NC-200, NC-202, NC-203, NC-250, NC-3000) for routine cell counting, the higher-throughput XcytoMatic platform (XM30, XM40) for cGMP bioprocessing, and the Ovizio iLine F PRO holographic microscope acquired in October 2024 for in-process monitoring. Supporting software includes XM Octopus for centralized fleet management, predictive modeling, and 21 CFR Part 11-compliant data handling, plus XM-View and NC-View for instrument analysis.

The company's primary customers are cell-and-gene-therapy manufacturers (CAR-T, CAR-NK, TILs, dendritic vaccines), biopharmaceutical and vaccine producers, bioprocess development labs, academic research institutions, and animal-reproduction operations. Revenue is generated through three streams: one-time instrument sales, recurring consumables (cassettes and reagents), and a service portfolio that includes GMP-Ready Service Plans, validation plans, IQ/OQ protocols, and training/certification services. The company sells primarily through a direct enterprise field-sales organization with quote-based pricing, supported by free product demonstrations, industry conferences, webinars, and content marketing. ChemoMetec is publicly listed on Nasdaq Copenhagen under ticker CHEMM and reports FY2025/26 revenue guidance of DKK 565-580M and EBITDA of DKK 320-335M, with Q3 2025/26 delivering DKK 142.3M in revenue (+15% YoY) and DKK 84.5M in EBITDA at a 59% margin.

Short descriptiontext

ChemoMetec A/S is a Danish public medtech company that designs automated fluorescence-based cell counting instruments and proprietary disposable cassettes for pharmaceutical, biotech, and academic customers in cell-and-gene-therapy, bioprocessing, and research applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAllerød, Denmark
HQ citystring
Allerød
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated cell counting, fluorescence image cytometry, bioprocessing cell analysis, cell therapy manufacturing, GMP compliant instrumentation
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Laboratory Cell Counting Instruments
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeOne Time License
Description

Sale of automated cell counters and analyzers (NucleoCounter NC-200, NC-202, NC-203, NC-250, NC-3000, XcytoMatic 30, XcytoMatic 40, SP-100). Instruments are high-precision capital equipment sold directly to pharmaceutical, biotech, and research customers. Q3 2025/26 showed strong instrument sales growth with XcytoMatic products more than quadrupling to DKK 14.6 million.

globenewswire.com
2Consumables (Cassettes, Reagents, Slides)
TypeUsage Based
Description

Recurring revenue from proprietary disposable cassettes (Via1, Via2, Via3), reagents, and slides required for instrument operation. Consumables declined 10% in Q3 2025/26 due to lower activity in existing approved therapies.

chemometec.com
3Service Plans and Support
TypeSubscription Recurring
Description

Annual service plans (GMP-Ready Service Plans, standard Service Plans) and validation plans that provide regular instrument qualification, compliance support, and priority technical assistance.

chemometec.com
4Training and Certification
TypeProfessional Services
Description

On-site operator training and certification programs for GMP manufacturing staff, conducted by ChemoMetec instructors with certification through theoretical and hands-on testing.

chemometec.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom enterprise pricing based on instrument model, service plan tier, and volume
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing is quote-based. Instruments offered with optional GMP-Ready Service Plan and standard Service Plan. Training programs available as add-on service.

chemometec.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1XcytoMatic
Description

High-throughput automated cell counters for cGMP biomanufacturing, including XcytoMatic 40 and XcytoMatic 30 models

chemometec.com
+5 more records
Core offering1 text field

ChemoMetec develops, manufactures, and sells automated cell counting and analysis instruments using fluorescence-based image cytometry combined with proprietary disposable cassette technology. The product portfolio includes the NucleoCounter and XcytoMatic instrument lines, the Ovizio iLine F PRO holographic microscope, proprietary Via-cassette consumables, and GMP-ready software platforms. Products serve pharmaceutical, biotech, and academic customers for cell counting in research, bioprocess monitoring, and GMP-compliant cell therapy manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Instrument-to-instrument variation under 5% (XcytoMatic 40)
+4 more records
Product overview1 text field

ChemoMetec offers a comprehensive portfolio of automated cell counting and analysis instruments designed, manufactured, and tested in Denmark since 1997. The current product line centers on the XcytoMatic platform (XcytoMatic 40 and XcytoMatic 30) and NucleoCounter NC-203 for modern bioprocessing and cGMP manufacturing, complemented by software platforms (XM Octopus for centralized fleet management and XM-View/NC-View for analysis). The NucleoCounter legacy line (NC-200, NC-250, NC-3000) continues until April 2027 with service support through 2029. Specialized instruments include the SP-100 sperm counter. The acquired Ovizio iLine F PRO provides holographic microscopy for continuous bioprocess monitoring. All instruments use proprietary cassette technology (Via1, Via2, Via3) with pre-loaded fluorescent dyes for consistent, error-free cell counting. The company serves biotech, pharma, and academic segments worldwide.

Product and service17 records
1XcytoMatic 40 (XM40)
CategoryCore Product
Description

High-throughput cell density analyzer capable of processing approximately 100 samples per hour with up to 100 million cells/ml counting range. Combines brightfield and fluorescence microscopy with AI-powered XM-View software for automated debris tracking and cell diameter measurement. Designed for cGMP manufacturing of biologics, vaccines, and advanced therapies.

2XcytoMatic 30 (XM30)
CategoryCore Product
Description

Flexible automated cell counter supporting both fully automated integrations and manual walk-up operation. Features API access for automated data retrieval and integrates with pipetting robots and bioreactors for hands-free cell counting workflows.

3NucleoCounter NC-203
CategoryCore Product
Description

High-precision cell counter combining cassette-based technology with brightfield imaging for robust differentiation between cells and debris. Uses XM-View software with API access for automated data retrieval and GMP/21 CFR Part 11 compliance.

4NucleoCounter NC-202
CategoryCore Product
Description

Third-generation automated cell counter featuring upgraded hardware and NC-View software. Delivers consistent results across instruments, users, and sites with DebrisIndex feature for measuring culture debris build-up. GMP/21 CFR Part 11 ready.

5NucleoCounter NC-200
CategoryLegacy Product
Description

High-precision automated cell counter using image cytometry for counting suspension cells, aggregated cells, CAR-T cells, stem cells, and cells on microcarriers. Will be discontinued and available only until April 2027.

6NucleoCounter NC-250
CategoryLegacy Product
Description

Automated cell analyzer with fluorescence imaging for characterizing cell properties. Offers optimized protocols for mammalian cells and unique assays for cells on microcarriers and sphere cultures. Available only until April 2027.

7NucleoCounter NC-3000
CategoryLegacy Product
Description

Advanced image cytometer using fluorescence imaging for high-speed analytical assays of mammalian, yeast, and insect cells. Features 5-minute cell cycle assay, apoptosis assays, and GFP assay with FlexiCyte customization option. Available only until April 2027.

8NucleoCounter SP-100
CategorySpecialized Product
Description

Automated sperm cell counter designed for animal reproduction applications. Determines total sperm concentration and viability from ejaculates or extended doses with virtually unlimited measurement range.

9Ovizio iLine F PRO Analyzer
CategoryAcquired Brand
Description

Online holographic microscope for continuous monitoring of critical quality attributes in bioprocesses. Works with wave bags, single-use and stirred tank bioreactors. Features machine learning algorithms for cell detection and parameter tracking, cGMP compliant.

10XM Octopus
CategoryPlatform
Description

Centralized laboratory automation platform that integrates multiple instruments into unified workflows, enabling remote control, fleet management, quality control, and AI-powered predictive models. Supports REST API and WebSocket communication for real-time data acquisition and control.

11XM-View Software
CategorySoftware
Description

Shared software platform across XcytoMatic series and NC-203 instruments. Provides AI-powered analysis, API access for automated data retrieval, and 21 CFR Part 11 compliance for GMP environments.

12NC-View Software
CategorySoftware
Description

Software for NucleoCounter NC-202 providing data traceability with secure audit trail format. Compatible with 21 CFR Part 11 (EU Annex 11) and integrates into GMP setups with Secure Mode software package.

13Via3-Cassette
CategoryConsumable
Description

Disposable cassette with pre-loaded fluorescent stains (AO and DAPI) for use with NucleoCounter NC-203. Creates closed cell-counting system eliminating pipetting errors and reagent exposure.

14Via2-Cassette
CategoryConsumable
Description

Volume-calibrated disposable cassette with pre-loaded AO and DAPI stains for NucleoCounter NC-202. Eliminates pipetting errors and provides consistent cell counts across instruments and users.

15Via1-Cassette
CategoryConsumable
Description

Disposable cassette with pre-loaded fluorescent stains for NucleoCounter NC-200 and NC-3000 instruments. Volume-calibrated to ensure high-precision counts and cell reproducibility.

16GMP-Ready Service Plans and Validation Plans
CategoryService
Description

Annual service plans (GMP-Ready Service Plans and standard Service Plans) and validation plans that provide regular instrument qualification, compliance support, and priority technical assistance for NucleoCounter and XcytoMatic instruments.

17Operator Training and Certification
CategoryService
Description

On-site operator training and certification programs for GMP manufacturing staff, conducted by ChemoMetec instructors with certification through theoretical and hands-on testing.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-08-10
Description

Collaboration to develop and commercialize a connection kit linking Roche's Cedex Bio Analyzer with ChemoMetec's Xcytomatic 30 cell counter. Roche handles design and validation of the connection kit; both companies co-promote the combined solution while remaining sole sellers of their respective instruments. This partnership enhances integration capabilities for bioprocessing customers requiring connected analytics.

Strategic tierPreferredTypeTechnology or Integration
Description

Listed as a preferred partner on ChemoMetec's website, indicating an established working relationship for complementary product integration or distribution in laboratory automation workflows.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Through its Cell Analysis portfolio (xCELLigence, NovoCyte flow cytometry, ACEA Biosciences), Agilent covers cell counting and cell-based assay use cases in pharma/biotech. Comparable in target customer, broader in platform scope.

TypeDirect peer
Description

Provides bioprocess analytics including cell density and viability sensors for upstream cell culture monitoring in the same biomanufacturing customers ChemoMetec serves with NC-203 and XcytoMatic. Increasingly competing in continuous/on-line cell monitoring alongside the Ovizio iLine F PRO.

TypeEmerging player
Description

Japanese diagnostics leader expanding automated hematology and cell analysis capabilities into pharmaceutical/biotech QC. Less direct overlap than flow cytometry players but increasingly relevant for cell therapy process analytics.

TypeBroad incumbent
Description

Flow cytometry leader (BD Cell Viability kits, FACSChorus, FACSDiscover) used by biopharmaceutical and cell therapy manufacturers. Overlaps with ChemoMetec on cell-based QC but competes across a much broader product breadth.

TypeDirect peer
Description

Direct competitor in automated cell counting with the Vi-Cell series of cell viability analyzers targeting bioprocessing and research labs. Serves overlapping customer base with comparable cassette/sample-based fluorescence workflows.

6Sony Biotechnology
TypeEmerging player
Description

Developer of the CG-8000 cell sorter and MA900 multi-application cell sorter used in cell therapy manufacturing and cell biology research. Comparable in cell-therapy QC focus but with a different instrument category (sorters vs counters).

TypeDirect peer
Description

Sells the TC20 automated cell counter, which directly competes with ChemoMetec's NucleoCounter line for routine cell counting in research and academic labs. Uses disposable counting slides similarly to ChemoMetec's cassette model.

TypeBroad incumbent
Description

Major instrument incumbent with the Countess automated cell counter and a broad flow cytometry and cell analysis portfolio serving bioprocessing, cell therapy, and research customers. Competes across the same workflow but as part of a much wider life sciences offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChemoMetec

Laboratory Cell Counting Instrumentschemometec.com

ChemoMetec A/S is a Danish public medtech company that designs automated fluorescence-based cell counting instruments and proprietary disposable cassettes for pharmaceutical, biotech, and academic customers in cell-and-gene-therapy, bioprocessing, and research applications.

What ChemoMetec does

ChemoMetec A/S, founded in 1997 and headquartered in Allerød, Denmark, designs, manufactures, and sells automated cell counting and analysis instruments used by pharmaceutical, biotechnology, and academic customers to quantify cells in drug development, bioprocessing, and quality control. Its core technology is fluorescence-based image cytometry that uses proprietary, volume-calibrated disposable cassettes (Via1, Via2, Via3) to eliminate the subjectivity and pipetting error inherent in manual trypan-blue counting. The product portfolio spans the NucleoCounter family (NC-200, NC-202, NC-203, NC-250, NC-3000) for routine cell counting, the higher-throughput XcytoMatic platform (XM30, XM40) for cGMP bioprocessing, and the Ovizio iLine F PRO holographic microscope acquired in October 2024 for in-process monitoring. Supporting software includes XM Octopus for centralized fleet management, predictive modeling, and 21 CFR Part 11-compliant data handling, plus XM-View and NC-View for instrument analysis.

The company's primary customers are cell-and-gene-therapy manufacturers (CAR-T, CAR-NK, TILs, dendritic vaccines), biopharmaceutical and vaccine producers, bioprocess development labs, academic research institutions, and animal-reproduction operations. Revenue is generated through three streams: one-time instrument sales, recurring consumables (cassettes and reagents), and a service portfolio that includes GMP-Ready Service Plans, validation plans, IQ/OQ protocols, and training/certification services. The company sells primarily through a direct enterprise field-sales organization with quote-based pricing, supported by free product demonstrations, industry conferences, webinars, and content marketing. ChemoMetec is publicly listed on Nasdaq Copenhagen under ticker CHEMM and reports FY2025/26 revenue guidance of DKK 565-580M and EBITDA of DKK 320-335M, with Q3 2025/26 delivering DKK 142.3M in revenue (+15% YoY) and DKK 84.5M in EBITDA at a 59% margin.

ChemoMetec firmographics

Firmographics
Name
ChemoMetec
Legal name
ChemoMetec A/S
Website
https://chemometec.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
ChemoMetec A/S is a Danish public medtech company that designs automated fluorescence-based cell counting instruments and proprietary disposable cassettes for pharmaceutical, biotech, and academic customers in cell-and-gene-therapy, bioprocessing, and research applications.
Ownership category
akta.pro rank

ChemoMetec industry classification

Industry
Product category
Laboratory Cell Counting Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Automated cell counting
  • Fluorescence image cytometry
  • Bioprocessing cell analysis
  • Cell therapy manufacturing
  • GMP compliant instrumentation

Where ChemoMetec is headquartered

Location

Headquarters

HQ city
Allerød
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

ChemoMetec business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Instrument Sales: Sale of automated cell counters and analyzers (NucleoCounter NC-200, NC-202, NC-203, NC-250, NC-3000, XcytoMatic 30, XcytoMatic 40, SP-100). Instruments are high-precision capital equipment sold directly to pharmaceutical, biotech, and research customers. Q3 2025/26 showed strong instrument sales growth with XcytoMatic products more than quadrupling to DKK 14.6 million.
  2. Consumables (Cassettes, Reagents, Slides): Recurring revenue from proprietary disposable cassettes (Via1, Via2, Via3), reagents, and slides required for instrument operation. Consumables declined 10% in Q3 2025/26 due to lower activity in existing approved therapies.
  3. Service Plans and Support: Annual service plans (GMP-Ready Service Plans, standard Service Plans) and validation plans that provide regular instrument qualification, compliance support, and priority technical assistance.
  4. Training and Certification: On-site operator training and certification programs for GMP manufacturing staff, conducted by ChemoMetec instructors with certification through theoretical and hands-on testing.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCustom enterprise pricing based on instrument model, service plan tier, and volume

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

ChemoMetec product offering

Product offering

Core offering

ChemoMetec develops, manufactures, and sells automated cell counting and analysis instruments using fluorescence-based image cytometry combined with proprietary disposable cassette technology. The product portfolio includes the NucleoCounter and XcytoMatic instrument lines, the Ovizio iLine F PRO holographic microscope, proprietary Via-cassette consumables, and GMP-ready software platforms. Products serve pharmaceutical, biotech, and academic customers for cell counting in research, bioprocess monitoring, and GMP-compliant cell therapy manufacturing.

Product overview

ChemoMetec offers a comprehensive portfolio of automated cell counting and analysis instruments designed, manufactured, and tested in Denmark since 1997. The current product line centers on the XcytoMatic platform (XcytoMatic 40 and XcytoMatic 30) and NucleoCounter NC-203 for modern bioprocessing and cGMP manufacturing, complemented by software platforms (XM Octopus for centralized fleet management and XM-View/NC-View for analysis). The NucleoCounter legacy line (NC-200, NC-250, NC-3000) continues until April 2027 with service support through 2029. Specialized instruments include the SP-100 sperm counter. The acquired Ovizio iLine F PRO provides holographic microscopy for continuous bioprocess monitoring. All instruments use proprietary cassette technology (Via1, Via2, Via3) with pre-loaded fluorescent dyes for consistent, error-free cell counting. The company serves biotech, pharma, and academic segments worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • XcytoMatic: High-throughput automated cell counters for cGMP biomanufacturing, including XcytoMatic 40 and XcytoMatic 30 models
  • NucleoCounter
  • XM Octopus
  • Via2-Cassette
  • NC-View
  • XM-View

Products and services

  • XcytoMatic 40 (XM40) High-throughput cell density analyzer capable of processing approximately 100 samples per hour with up to 100 million cells/ml counting range. Combines brightfield and fluorescence microscopy with AI-powered XM-View software for automated debris tracking and cell diameter measurement. Designed for cGMP manufacturing of biologics, vaccines, and advanced therapies.
  • XcytoMatic 30 (XM30) Flexible automated cell counter supporting both fully automated integrations and manual walk-up operation. Features API access for automated data retrieval and integrates with pipetting robots and bioreactors for hands-free cell counting workflows.
  • NucleoCounter NC-203 High-precision cell counter combining cassette-based technology with brightfield imaging for robust differentiation between cells and debris. Uses XM-View software with API access for automated data retrieval and GMP/21 CFR Part 11 compliance.
  • NucleoCounter NC-202 Third-generation automated cell counter featuring upgraded hardware and NC-View software. Delivers consistent results across instruments, users, and sites with DebrisIndex feature for measuring culture debris build-up. GMP/21 CFR Part 11 ready.
  • NucleoCounter NC-200 High-precision automated cell counter using image cytometry for counting suspension cells, aggregated cells, CAR-T cells, stem cells, and cells on microcarriers. Will be discontinued and available only until April 2027.
  • NucleoCounter NC-250 Automated cell analyzer with fluorescence imaging for characterizing cell properties. Offers optimized protocols for mammalian cells and unique assays for cells on microcarriers and sphere cultures. Available only until April 2027.
  • NucleoCounter NC-3000 Advanced image cytometer using fluorescence imaging for high-speed analytical assays of mammalian, yeast, and insect cells. Features 5-minute cell cycle assay, apoptosis assays, and GFP assay with FlexiCyte customization option. Available only until April 2027.
  • NucleoCounter SP-100 Automated sperm cell counter designed for animal reproduction applications. Determines total sperm concentration and viability from ejaculates or extended doses with virtually unlimited measurement range.
  • Ovizio iLine F PRO Analyzer Online holographic microscope for continuous monitoring of critical quality attributes in bioprocesses. Works with wave bags, single-use and stirred tank bioreactors. Features machine learning algorithms for cell detection and parameter tracking, cGMP compliant.
  • XM Octopus Centralized laboratory automation platform that integrates multiple instruments into unified workflows, enabling remote control, fleet management, quality control, and AI-powered predictive models. Supports REST API and WebSocket communication for real-time data acquisition and control.
  • XM-View Software Shared software platform across XcytoMatic series and NC-203 instruments. Provides AI-powered analysis, API access for automated data retrieval, and 21 CFR Part 11 compliance for GMP environments.
  • NC-View Software Software for NucleoCounter NC-202 providing data traceability with secure audit trail format. Compatible with 21 CFR Part 11 (EU Annex 11) and integrates into GMP setups with Secure Mode software package.
  • Via3-Cassette Disposable cassette with pre-loaded fluorescent stains (AO and DAPI) for use with NucleoCounter NC-203. Creates closed cell-counting system eliminating pipetting errors and reagent exposure.
  • Via2-Cassette Volume-calibrated disposable cassette with pre-loaded AO and DAPI stains for NucleoCounter NC-202. Eliminates pipetting errors and provides consistent cell counts across instruments and users.
  • Via1-Cassette Disposable cassette with pre-loaded fluorescent stains for NucleoCounter NC-200 and NC-3000 instruments. Volume-calibrated to ensure high-precision counts and cell reproducibility.
  • GMP-Ready Service Plans and Validation Plans Annual service plans (GMP-Ready Service Plans and standard Service Plans) and validation plans that provide regular instrument qualification, compliance support, and priority technical assistance for NucleoCounter and XcytoMatic instruments.
  • Operator Training and Certification On-site operator training and certification programs for GMP manufacturing staff, conducted by ChemoMetec instructors with certification through theoretical and hands-on testing.

Quantifiable outcome

  • Instrument-to-instrument variation under 5% (XcytoMatic 40)
  • +4 more outcomes

Companies that use ChemoMetec

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

ChemoMetec technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature7 records

ChemoMetec partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and preferred.

  • Roche DiagnosticscoreStrategic or Co-development Partner · 10 August 2026Collaboration to develop and commercialize a connection kit linking Roche's Cedex Bio Analyzer with ChemoMetec's Xcytomatic 30 cell counter. Roche handles design and validation of the connection kit; both companies co-promote the combined solution while remaining sole sellers of their respective instruments. This partnership enhances integration capabilities for bioprocessing customers requiring connected analytics.
  • TecanpreferredTechnology or IntegrationListed as a preferred partner on ChemoMetec's website, indicating an established working relationship for complementary product integration or distribution in laboratory automation workflows.

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

ChemoMetec competitors and assessment

Company assessment

Broad incumbents

  • Agilent Technologies: Through its Cell Analysis portfolio (xCELLigence, NovoCyte flow cytometry, ACEA Biosciences), Agilent covers cell counting and cell-based assay use cases in pharma/biotech. Comparable in target customer, broader in platform scope.
  • Becton Dickinson (BD Biosciences): Flow cytometry leader (BD Cell Viability kits, FACSChorus, FACSDiscover) used by biopharmaceutical and cell therapy manufacturers. Overlaps with ChemoMetec on cell-based QC but competes across a much broader product breadth.
  • Thermo Fisher Scientific: Major instrument incumbent with the Countess automated cell counter and a broad flow cytometry and cell analysis portfolio serving bioprocessing, cell therapy, and research customers. Competes across the same workflow but as part of a much wider life sciences offering.

Direct peers

  • Sartorius: Provides bioprocess analytics including cell density and viability sensors for upstream cell culture monitoring in the same biomanufacturing customers ChemoMetec serves with NC-203 and XcytoMatic. Increasingly competing in continuous/on-line cell monitoring alongside the Ovizio iLine F PRO.
  • Beckman Coulter Life Sciences: Direct competitor in automated cell counting with the Vi-Cell series of cell viability analyzers targeting bioprocessing and research labs. Serves overlapping customer base with comparable cassette/sample-based fluorescence workflows.
  • Bio-Rad Laboratories: Sells the TC20 automated cell counter, which directly competes with ChemoMetec's NucleoCounter line for routine cell counting in research and academic labs. Uses disposable counting slides similarly to ChemoMetec's cassette model.

Emerging players

  • Sysmex Corporation: Japanese diagnostics leader expanding automated hematology and cell analysis capabilities into pharmaceutical/biotech QC. Less direct overlap than flow cytometry players but increasingly relevant for cell therapy process analytics.
  • Sony Biotechnology: Developer of the CG-8000 cell sorter and MA900 multi-application cell sorter used in cell therapy manufacturing and cell biology research. Comparable in cell-therapy QC focus but with a different instrument category (sorters vs counters).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

ChemoMetec social profiles

Digital presence

ChemoMetec compliance and trust

Trust signal

Compliance7 records

ChemoMetec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChemoMetec leadership team

Management profile

Number of profiles

Profiles4 records

ChemoMetec subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ChemoMetec funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChemoMetec M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemoMetec

What does ChemoMetec do?

ChemoMetec develops, manufactures, and sells automated cell counting and analysis instruments using fluorescence-based image cytometry combined with proprietary disposable cassette technology. The product portfolio includes the NucleoCounter and XcytoMatic instrument lines, the Ovizio iLine F PRO holographic microscope, proprietary Via-cassette consumables, and GMP-ready software platforms. Products serve pharmaceutical, biotech, and academic customers for cell counting in research, bioprocess monitoring, and GMP-compliant cell therapy manufacturing.

Is ChemoMetec a public or private company?

ChemoMetec is a public company. It is classified as public and is currently operating.

When was ChemoMetec founded?

ChemoMetec was founded in 1997. It employs 101 to 250 people.

Where is ChemoMetec based?

ChemoMetec is headquartered in Allerød, Denmark, in the Europe region.

How does ChemoMetec make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables (Cassettes, Reagents, Slides), service Plans and Support and training and Certification.

Who are ChemoMetec's main competitors?

Broad incumbents on record are Agilent Technologies, Becton Dickinson (BD Biosciences) and Thermo Fisher Scientific. Direct peers are Sartorius, Beckman Coulter Life Sciences and Bio-Rad Laboratories. Emerging players are Sysmex Corporation and Sony Biotechnology.

Does ChemoMetec have an API?

Yes. XM Octopus™ provides a REST API and WebSocket protocols for real-time instrument control, data exchange, and third-party system integration. The platform enables remote instrument operation, centralized data governance, and real-time operational oversight. Additionally, the Ovizio iLine F PRO Analyzer supports automation via RESTful web services (OPC ready). The NucleoCounter NC-203 provides API access through XM-View software for automated data retrieval and seamless integration into broader data-management architectures.

What industry is ChemoMetec in?

ChemoMetec's product category is Laboratory Cell Counting Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooIs ChemoMetec (CPSE:CHEMM) Fully Valued As It Raises 2026 27 Revenue Guidance?ChemoMetec raised its 2026/27 revenue guidance to DKK 570-605 million, following insider share transactions. The stock rose 5.14% in one day, but a 11% overvaluation narrative cites a fair value of DKK 638. Risks include heavy automation spending failing to drive consumables demand.Seeking AlphaChemoMetec A/S (CHHMF) Q1 2027 Earnings Call TranscriptChemoMetec reported Q1 revenue of DKK 160 million, up 28% year-over-year, with EBITDA of DKK 100.3 million, up 46%. The EBITDA margin reached 63% from 55% last year, driven by higher revenue and improved gross margins on XM products.Business & FinancialNotification Of Managers' TransactionsChemoMetec A/S notified regulators of share transactions by its CEO Martin Helbo Behrens and CFO Phillip Massie Price under EU Regulation 596/2014. The notification, dated 6 November 2026, details the transactions in the company's shares, with contact information provided for both executives.TradingViewNotification of managers’ transactionsChemoMetec A/S notified authorities of share transactions by its managers and closely associated persons under EU Regulation 596/2014. The notification, dated November 2026, references transactions by Phillip Massie Price, CFO, and lists the CEO and CFO contact details.TradingViewChemoMetec A/S (CHEMM) Reports CFO Share TransactionsChemoMetec A/S notified regulators under EU MAR Article 19 of CFO Phillip Massie Price's share transactions. The release provides no details on trade size, price, or direction, so the impact on sentiment is unclear.GlobeNewswireIndberetning af ledende medarbejderes transaktionerChemoMetec A/S received a report of transactions in its own shares executed by a person with leadership responsibility or closely connected, as required under EU Regulation 596/2014. The report concerns Phillip Massie Price, CFO, and is attached as a PDF. The company's CEO Martin Helbo Behrens confirmed receipt.GlobeNewswireNotification of managers’ transactionsChemoMetec A/S notified regulators of share transactions by its managers and closely associated persons under EU Regulation 596/2014. The notification, dated 6 November 2026, references transactions by Phillip Massie Price, CFO, and lists the CEO and CFO contact details.TradingViewChemoMetec A/S (CHEMM) BlackRock's Share Voting Rights Fall Below 15%BlackRock's share voting rights in ChemoMetec fell to 14.95% on 2 November 2026, below the 15% disclosure threshold. Its aggregate position, including 0.13% from financial instruments, remained at 15.08%. The reduction does not change its aggregate stake.The future of tradingChemoMetec Q1 2026/27 EBITDA jumps 46% year-on-year to DKK 100.3 millionChemoMetec reported Q1 2026/27 EBITDA of DKK 100.3 million, up 46% year-on-year, with revenue of DKK 160 million, up 28%. Instrument revenue rose 61% to DKK 65.6 million, and NC-203 revenue exceeded DKK 20 million. The company maintained its 2026/27 revenue guidance of DKK 570–605 million and EBITDA guidance of DKK 335–360 million.Business & FinancialUpgrade Of Revenue And Operating Profit GuidanceChemoMetec upgraded its 2026/27 revenue guidance to DKK 570-605 million and EBITDA to DKK 335-360 million, citing higher-than-expected demand for its NC-203 instrument. Q1 2026/27 revenue rose 28% to DKK 160.0 million, with EBITDA margin at 63% versus 55% a year earlier.